ArticleFrontiers in medicine2018
Considering Cell Therapy Product "Good Manufacturing Practice" Status.
Article in Frontiers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Human endothelial colony-forming cells in regenerative therapy: A systematic review of controlled preclinical animal studies.Stem cells translational medicine · 2020Pooled it
- Bioprinted Constructs in the Regulatory Landscape: Current State and Future Perspectives.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Airway epithelial stem cell renewal and differentiation: overcoming challenging steps towards clinical-grade tissue engineering.Stem cell research & therapy · 2025Article
- [3D printing in surgery: relevance of technology maturity assessment in bioprinting research studies].Chirurgie (Heidelberg, Germany) · 2025Review
- The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management.Advanced pharmaceutical bulletin · 2024Review
- Article
- Lessons learnt, and still to learn, in first in human stem cell trials.Stem cell reports · 2023Review
- Advancing cell-based cancer immunotherapy through stem cell engineering.Cell stem cell · 2023Review
- Exosomes for angiogenesis induction in ischemic disorders.Journal of cellular and molecular medicine · 2023Review
- Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation.Stem cell research & therapy · 2022Review
- Article
- Approaches for the isolation and long-term expansion of pericytes from human and animal tissues.Frontiers in cardiovascular medicine · 2022Article
- Promises and challenges of adoptive T-cell therapies for solid tumours.British journal of cancer · 2021Review
- Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs.Stem cell reviews and reports · 2021Review
- Nanoengineering the surface of corneal implants: towards functional anti-microbial and biofilm materials.RSC advances · 2020Article
- Cell-Based Therapy Manufacturing in Stirred Suspension Bioreactor: Thoughts for cGMP Compliance.Frontiers in bioengineering and biotechnology · 2020Review
- Emerging Methods for Enhancing Pluripotent Stem Cell Expansion.Frontiers in cell and developmental biology · 2020Review
- Regenerative Features of Adipose Tissue for Osteoarthritis Treatment in a Rabbit Model: Enzymatic Digestion Versus Mechanical Disruption.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.